DUBAI: Pfizer Inc. on Tuesday raised its forecast for annual sales of its COVID-19 vaccine by $2 billion to $34 billion on demand for omicron-targeted boosters, helping allay some investor worries over growth for the vaccinations.
The US drugmaker’s shares rose 2.4 percent to $447.67 in morning trading as its third-quarter profit beat estimates, mainly due to better-than-expected sales of the vaccine.
The upbeat earnings also sent shares of rival COVID-19 vaccine makers higher. Novavax Inc. rose 11 percent, while Moderna Inc. gained about 4 percent.
In a statement, Türk urged Iranian authorities to halt all executions and move toward the…
The latest Russian attacks mark an increasingly deadly escalation in the ongoing war, with July…
“I am alarmed by the rise in executions and death sentences issued in Iran since…
Available for over a yearMore than six years since the start of the Covid pandemic,…
He said: "This investment in access, wellbeing and nature means more people can enjoy everything…
"In terms of arch support and joint support, it's not the best style, but people…